Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncoimmunology

• Publication date

  2018-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/2162402X.2017.1376155PMID 29296536PMCID PMC5739568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

  2017cited by this paper
• Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

  2016influential reference
• Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

  2016cited by this paper
• PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

  2016cited by this paper
• Novel signaling collaboration between TGF-β and adaptor protein Crk facilitates EMT in human lung cancer

  2016cited by this paper
• MYC regulates the antitumor immune response through CD47 and PD-L1

  2016cited by this paper
• Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

  2015cited by this paper
• Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

  2015cited by this paper
• CRK proteins selectively regulate T cell migration into inflamed tissues.

  2015cited by this paper
• Cyclophilin A promotes cell migration via the Abl-Crk signaling pathway

  2015cited by this paper
• Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells

  2015cited by this paper
• Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression*

  2015cited by this paper
• RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

  2015cited by this paper
• Prognostic and predictive value of PDL1 expression in breast cancer

  2014cited by this paper
• Crk at the Quarter Century Mark: Perspectives in Signaling and Cancer

  2014cited by this paper
• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression

  2014cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• Breakthrough of the year 2013. Cancer immunotherapy.

  2013cited by this paper
• The adaptor protein Crk controls activation and inhibition of natural killer cells.

  2012cited by this paper
• Roles for crk in cancer metastasis and invasion.

  2012cited by this paper
• Crk adaptor proteins act as key signaling integrators for breast tumorigenesis

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Immunity, inflammation, and cancer.

  2010cited by this paper
• Crk and CrkL adaptor proteins: networks for physiological and pathological signaling

  2009cited by this paper
• A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors

  2008cited by this paper
• Direct multiplexed measurement of gene expression with color-coded probe pairs

  2008cited by this paper
• Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors.

  2007cited by this paper
• The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway

  2006cited by this paper
• C‐terminal SH3 domain of CrkII regulates the assembly and function of the DOCK180/ELMO Rac‐GEF

  2005cited by this paper
• Cytokines in cancer pathogenesis and cancer therapy

  2004cited by this paper
• Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells.

  2000cited by this paper
• v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation.

  2000cited by this paper
• αvβ5 integrin recruits the CrkII–Dock180–Rac1 complex for phagocytosis of apoptotic cells

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways.

  1995cited by this paper
• c‐Abl kinase regulates the protein binding activity of c‐Crk.

  1994cited by this paper
• A 31-amino-acid N-terminal extension regulates c-Crk binding to tyrosine-phosphorylated proteins

  1993cited by this paper
• Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts

  1993cited by this paper
• Tyrosine-phosphorylated epidermal growth factor receptor and cellular p130 provide high affinity binding substrates to analyze Crk-phosphotyrosine-dependent interactions in vitro.

  1992cited by this paper

• Multiomic analysis of CCNE1 amplification associated molecular and immune features in gynecological cancers

  2025cites this paper
• Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition

  2025cites this paper
• The p130Cas-Crk/CrkL Axis: A Therapeutic Target for Invasive Cancers Unveiled by Collaboration Among p130Cas, Crk, and CrkL

  2025influential citation
• Immune evasion and resistance in breast cancer.

  2025cites this paper
• Exploring the Mechanisms of Epithelial-Mesenchymal Transition (EMT) in Breast Cancer: The Role of MicroRNA and the Therapeutic Promise of Bioactive Compounds from Edible Plants

  2025cites this paper
• Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle.

  2024cites this paper
• Cordycepin Triphosphate as a Potential Modulator of Cellular Plasticity in Cancer via cAMP-Dependent Pathways: An In Silico Approach

  2024cites this paper
• Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance

  2023cites this paper
• PD-1/PD-L1 axis in organ fibrosis

  2023cites this paper
• Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms

  2023cites this paper
• M1 macrophages induce PD-L1hi cell-led collective invasion in HPV-positive head and neck squamous cell carcinoma via TNF-α/CDK4/UPS14

  2023cites this paper
• Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer

  2023cites this paper
• Extracellular vesicle-mediated miR-126-3p transfer contributes to inter-cellular communication in the liver tumor microenvironment

  2023cites this paper
• PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.

  2022cites this paper
• CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis

  2022cites this paper
• Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

  2022cites this paper
• Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy

  2022cites this paper
• Bidirectional crosstalk between epithelial–mesenchymal plasticity and IFNγ-induced PD-L1 expression promotes tumour progression

  2022cites this paper
• Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity

  2022cites this paper
• Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.

  2022cites this paper
• MicroRNA-215-5p Inhibits the Proliferation and Migration of Wilm’s Tumor Cells by Targeting CRK

  2021cites this paper
• Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

  2021cites this paper
• Quantitative assessment of glioblastoma phenotypes in vitro establishes cell migration as a robust readout of Crk and CrkL activity

  2021cites this paper
• POU2F1 induces the immune escape in lung cancer by up-regulating PD-L1.

  2021cites this paper
• Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors

  2021cites this paper
• Crk and CrkL as Therapeutic Targets for Cancer Treatment

  2021influential citation
• Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma

  2021cites this paper
• Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer

  2021cites this paper
• Role of Calcium Homeostasis in Modulating EMT in Cancer

  2021cites this paper
• Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer.

  2020cites this paper
• Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

  2020cites this paper
• Crk1/2 and CrkL play critical roles in maintaining podocyte morphology and function.

  2020cites this paper
• Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer

  2020influential citation
• The Role of Ras-Associated Protein 1 (Rap1) in Cancer: Bad Actor or Good Player?

  2020cites this paper
• EMT signaling: potential contribution of CRISPR/Cas gene editing

  2020cites this paper
• The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System

  2019cites this paper
• Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

  2019cites this paper
• Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment

  2019cites this paper
• Advances of immune checkpoints in colorectal cancer treatment.

  2019cites this paper
• Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.

  2019cites this paper
• Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1

  2018cites this paper
• The Era of Immunotherapy in Breast Cancer

  2018cites this paper
• MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9

  2018cites this paper